content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange
  Commission on June 21, 2018</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 1.25in"><B>Registration No.
  333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 1.25in"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Therapix Biosciences Ltd.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
  charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State of Israel</B></FONT></TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of </FONT><BR>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Ariel Sharon Street</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HaShahar Tower, 16th Floor</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Givatayim, Israel </B></P></TD>
      <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5320047</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Therapix Biosciences Ltd. Israeli Share
  Option Plan (2005)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Therapix Biosciences Ltd. Israeli Share
  Option Plan (2015)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full Title of the Plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>C T Corporation System</B><BR>
  <B>111 Eighth Avenue</B><BR>
  <B>13th Floor</B><BR>
  <B>New York, New York 10011</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copies of communications to:</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jeffrey P. Schultz, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and
  Popeo P.C.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chrysler Center, 666 Third Avenue</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10017</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: 212-935-3000</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large
  accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See
  the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
      <TD STYLE="width: 37%">Large accelerated filer</TD>
      <TD STYLE="width: 8%"><FONT STYLE="font-family: Wingdings"></FONT>&#9744;</TD>
      <TD STYLE="width: 28%">Accelerated filer</TD>
      <TD STYLE="width: 27%; text-align: left">&nbsp;&#9744;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>Accelerated filer&#9;</TD>
      <TD>&#9744;</TD>
      <TD><P STYLE="margin: 0">Smaller <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting company</FONT></P>
  
  
  </TD>
      <TD STYLE="text-align: left">&nbsp;&#9744;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>Non-accelerated filer&#9;</TD>
      <TD>&#9746;</TD>
      <TD><P STYLE="margin: 0">Emerging <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">growth company</FONT></P>
  
  
  </TD>
      <TD STYLE="text-align: left">&nbsp;&#9746;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>(Do not check if a smaller reporting company)</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">If an emerging growth company, indicate by check mark
  if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act .&#9;<FONT STYLE="font-family: Wingdings">o</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Title of securities to be registered</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount to be </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>registered (2)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed maximum </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>offering price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;per share</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed maximum </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>aggregate </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>offering price</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount of </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>registration fee</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 52%">Ordinary Shares, par value NIS 0.10 per share (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">769,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">107,665.18</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13.40</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>Ordinary Shares, par value NIS 0.10 per share (1)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,880,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,340,800</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">415.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-bottom: 1.5pt">Ordinary Shares, par value NIS 0.10 per share (1)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,120,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.11</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,113,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">(5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138.59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">31,769,037</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,561,665.18</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">567.92</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
      <TD>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">American Depositary Shares (the &ldquo;<B>ADSs</B>&rdquo;),
          evidenced by American Depositary Receipts, issuable upon deposit of the Ordinary Shares registered hereby, par value NIS 0.10 per
          share (the &ldquo;<B>Ordinary Shares</B>&rdquo;), of Therapix Biosciences Ltd. (the &ldquo;<B>Registrant</B>&rdquo; or &ldquo;<B>Company</B>&rdquo;
          ) are registered on a separate registration statement on Form F-6 (File No. 333-197509). Each ADS represents forty (40) Ordinary
          Shares.</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">This Registration Statement on Form S-8 covers the following Ordinary Shares of Therapix Biosciences Ltd. (the &ldquo;<B>Registrant</B>&rdquo;):</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">(i) 769,037 Ordinary Shares issuable upon the exercise of options granted prior to the date hereof under the Registrant's Israeli Share Option Plan (2005) (the &ldquo;<B>2005 Plan</B>&rdquo;), (ii) 20,880,000 Ordinary Shares issuable upon the exercise of options granted prior to the date hereof under the Registrant's Israeli Share Option Plan (2015), as amended (the &ldquo;<B>2015 Plan</B>&rdquo;), (iii) 10,120,000 Ordinary Shares available for issuance pursuant to future grants under the 2015 Plan, and (iv) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), an indeterminate number of additional shares that may become issuable under the terms of the 2015 Plan by reason of any share split, share dividend, recapitalization or other similar transaction effected without the Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of the Registrant's Ordinary Shares.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of US$0.14 per share, the weighted average exercise price of the 1,090,361 Ordinary Shares issuable upon exercise of outstanding options under the 2005 Plan as of the date of this Registration Statement.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of US$0.l6 per share, the weighted average exercise price of the 23,100,000 Ordinary Shares issuable upon exercise of outstanding options under the 2015 Plan as of the date of this Registration Statement.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) and (c) on the basis of the average of the high and low prices of the Registrant's ADSs as reported on the Nasdaq Capital Market on June 20, 2018 with respect to Ordinary Shares reserved for issuance pursuant to future grants under the 2015 Plan.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.&nbsp;&nbsp;&nbsp;Plan
  Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.&nbsp;&nbsp;&nbsp;Registrant
  Information and Employee Plan Annual Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  
  
  
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* The documents containing the information specified in this
  Part I of Form S-8 (plan information and registration information and employee plan annual information) will be sent or given to
  employees as specified by the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) pursuant to Rule 428(b)(1)
  of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;). Such documents are not required to be and
  are not filed with the Commission either as part of this registration statement (this &ldquo;<B>Registration Statement</B>&rdquo;)
  or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference
  in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements
  of Section 10(a) of the Securities Act. The Registrant will provide a written statement to participants advising them of the availability
  without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including
  the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge,
  upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b), and will include the address
  and telephone number to which the request is to be directed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.&nbsp;&nbsp;&nbsp;Incorporation
  of Documents by Reference</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following documents filed by Therapix
  Biosciences Ltd. (the &ldquo;<B>Company</B>&rdquo;) are incorporated herein by reference:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px">&#9679;</TD>
      <TD><FONT STYLE="font-size: 10pt">Annual Report on Form 20-F for the year ended December 31, 2017, filed on April 30, 2018 (File No. 001-38041);</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px">&#9679;</TD>
      <TD><FONT STYLE="font-size: 10pt">Our Reports on Form 6-K filed on January 16, 2018, March 20, 2018, April 9, 2018, April 20, 2018, April 27, 2018, May 4, 2018, May 9, 2018, May 17, 2018, June 6, 2018 and June 14, 2018; and</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px">&#9679;</TD>
      <TD><FONT STYLE="font-size: 10pt">the description of our ADSs and ordinary shares contained in our Form 8-A filed on March 21, 2017 (File No. 001-38041).</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the foregoing, all documents
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended
  (the &ldquo;<B>Exchange Act</B>&rdquo;), prior to the filing of a post-effective amendment indicating that all securities offered
  hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference in
  this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained herein or
  in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be
  modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other
  subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
  this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4.&nbsp;&nbsp;&nbsp;Description
  of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.&nbsp;&nbsp;&nbsp;Interests
  of Named Experts and Counsel</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6.&nbsp;&nbsp;&nbsp;Indemnification
  of Directors and Officers</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Indemnification</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli Companies Law (5759-1999) (the
  &ldquo;<B>Companies Law</B>&rdquo;) and our articles of association provide that the Registrant may indemnify an office holder
  against:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">a financial liability imposed on him or her in favor
  of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement
  or arbitrator&rsquo;s award approved by a court; However, if an undertaking to indemnify an office holder with respect to such
  liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the Board of Directors,
  can be foreseen based on the company&rsquo;s activities when the undertaking to indemnify is given, and to an amount or according
  to criteria determined by the Board of Directors as reasonable under the circumstances, and such undertaking must detail the abovementioned
  foreseen events and amount or criteria;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&rsquo;
  fees, incurred by the office holder: (i) as a result of an investigation or proceeding instituted against him or her by an authority
  authorized to conduct such investigation or proceeding, provided that (a) no indictment (as defined in the Companies Law) was
  filed against such office holder as a result of such investigation or proceeding; and (b) no financial liability as a substitute
  for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or
  proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof
  of criminal intent; and (ii) in connection with a monetary sanction;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&rsquo;
  fees, expended by the office holder or charged to him or her by a court relating to an act performed in his or her capacity as
  an office holder, in connection with: (1) proceedings that the company institutes, or that another person institutes on the company&rsquo;s
  behalf, against him or her; (2) a criminal charge of which he or she was acquitted; or (3) a criminal charge for which he or she
  was convicted for a criminal offense that does not require proof of criminal thought;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">expenses incurred by an office holder relating to an administrative
  enforcement proceeding conducted with regard to such office holder, including reasonable litigation expenses and including attorneys&rsquo;
  fees;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">payment to the party injured by the violation; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">liability or expense otherwise permitted as an indemnification
  by the Companies Law.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left">Our articles of association allow us to indemnify
  our office holders up to a certain amount. The Companies Law also permits a company to undertake in advance to indemnify an office
  holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the
  undertaking should be limited:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">to categories of events that the Board of Directors determines
  are likely to occur in light of the operations of the company at the time that the undertaking to indemnify is made; and</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 48px; text-align: left">&#9679;</TD><TD STYLE="text-align: left">in amount or criterion determined by the Board of Directors,
  at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into indemnification agreements,
  which were amended following the consummation of our U.S. initial public offering and listing on NASDAQ, with each of our directors
  and with certain members of our senior management. Each such indemnification agreement provides the office holder with indemnification
  to the fullest extent permitted under applicable law and up to a certain amount, and including with respect to liabilities resulting
  from our March 2017 initial public offering in the United States, and to the extent that the directors and officers insurance do
  not cover these liabilities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Exculpation</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, an Israeli company
  may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an office
  holder from his or her liability to the company, in whole or in part, and for damages caused to the company as a result of a breach
  of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
  in its articles of association. A company may not exculpate a director from liability arising out of a prohibited dividend or distribution
  to shareholders. Our articles of association provide that we may exculpate any office holder from liability to us to the fullest
  extent permitted by law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into exculpation agreements
  with each of our current directors and executive officers undertaking to exculpate and release our office holders from any and
  all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law and including
  with respect to liabilities resulting from our March 2017 initial public offering in the United States.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Limitations</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law provides that we may not
  exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred
  as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
  or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act
  would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally
  or recklessly (as opposed to merely negligently); (3) any action taken or omission committed with the intent to derive an illegal
  personal benefit; or (4) any fine or forfeit levied against the office holder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have obtained directors and officers liability
  insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder
  to the fullest extent permitted by the Companies Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as the indemnification for liabilities
  arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or persons
  controlling the registrant, we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification
  is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.&nbsp;&nbsp;&nbsp;Exemption
  from Registration Claimed</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.&nbsp;&nbsp;&nbsp;Exhibits</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exhibits listed on the exhibit index
  at the end of this Registration Statement are included in this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.&nbsp;&nbsp;&nbsp;Undertakings</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned Registrant, Therapix Biosciences
  Ltd., hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>provided</U>, <U>however</U>, that paragraphs
  (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the
  Exchange Act that are incorporated by reference in the registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">that, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; and</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Registrant hereby undertakes that, for
  purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Sections
  13(a) or 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to
  the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
  controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
  on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Givatayim, Israel, on June 21, 2018.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">THERAPIX BIOSCIENCES LTD.</FONT></TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: white 3pt solid">&nbsp;</TD>
      <TD STYLE="border-bottom: white 3pt solid"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
      <TD NOWRAP STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Ascher Shmulewitz</FONT></TD>
      </TR>
  <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD NOWRAP STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Name: Ascher Shmulewitz, M.D, Ph.D.</FONT></TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD>
      </TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="pow_001"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">KNOW ALL MEN BY THESE PRESENTS that each
  person whose signature appears below hereby constitutes and appoints Dr. Ascher Shmulewitz and Oz Adler, and each of them, his
  true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution,
  for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection
  therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority
  to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either
  of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, as amended, this registration statement has been signed by the following persons on June 21, 2018 in the capacities
  indicated:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 30%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Signature and Name</B></FONT></TD>
      <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 41%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ascher Shmulewitz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Chairman of the Board of Directors and Chief</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Ascher Shmulewitz, M.D, Ph.D.</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>Executive Officer (Principal Executive Officer)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oz Adler&nbsp;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial and</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>Accounting Officer)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Amit Berger &nbsp;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Amit Berger</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Yafit Stark&nbsp;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Dr. Yafit Stark</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric So</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Eric So</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Zohar Heiblum</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Zohar Heiblum</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen M. Simes</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 21, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Stephen M. Simes</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE
  IN THE UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Securities Act of 1933,
  as amended, the undersigned, C T Corporation System, the duly authorized representative in the United States of Therapix Biosciences
  Ltd., has signed this registration statement on June 21, 2018.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">C T Corporation System</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Brian Mueller</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Brian Mueller</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Assistant Secretary</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
      <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 89%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1201935/000101915516000769/therapixdepnrec.htm"><FONT STYLE="font-size: 10pt">Form of Amended and Restated Depositary Agreement (filed as Exhibit 1 to the&nbsp;Post-Effective Amendment&nbsp;No. 1 to Form F-6 (File No. 333-197509) filed on December 7, 2016, and incorporated herein by reference).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="fs82018ex5-1_therapixbiosci.htm">Opinion of Horn &amp; Co. - Law Offices, Israeli counsel to the Registrant, as to the validity of the ordinary shares (including consent)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="fs82018ex23-1_therapixbiosci.htm">Consent of Kost Forer Gabbay &amp; Kasierer (A Member of Ernst &amp; Young Global), independent registered public accounting firm</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="fs82018ex5-1_therapixbiosci.htm">Consent of Horn &amp; Co. - Law Offices (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="#pow_001">Power of Attorney (included in the signature page to this Registration Statement)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390016017994/ff12016ex10vi_therapix.htm">Therapix Biosciences Ltd. Israeli Share Option Plan (2005) (filed as Exhibit 10.6 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on November 4, 2016, and incorporated herein by reference).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390016017994/ff12016ex10v_therapix.htm">Therapix Biosciences Ltd. Israeli Share Option Plan (2015) (filed as Exhibit 10.5 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on November 4, 2016, and incorporated herein by reference)</A></FONT></TD></TR>
  </TABLE>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 10; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  
  <P STYLE="margin: 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "fs82018_therapixbiosciences.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 70591}]
metadata_filer: {"company-data": {"conformed-name": "Therapix Biosciences Ltd.", "cik": "0001611746", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "L3", "fiscal-year-end": "1213"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-225773", "film-number": "18911527"}, "business-address": {"street1": "4 ARIEL SHARON STREET", "street2": "HASHAHAR TOWER, 16TH FLOOR", "city": "GIV?ATAYIM", "state": "L3", "zip": "5320047", "phone": "972-3-6167055"}, "mail-address": {"street1": "4 ARIEL SHARON STREET", "street2": "HASHAHAR TOWER, 16TH FLOOR", "city": "GIV?ATAYIM", "state": "L3", "zip": "5320047"}}
text: As filed with the Securities and Exchange
  Commission on June 21, 2018
  Registration No.
  333-
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER THE
  SECURITIES ACT OF 1933
  Therapix Biosciences Ltd.
  (Exact name of registrant as specified in
  charter)
  State of Israel
  Not Applicable
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  4 Ariel Sharon Street
  HaShahar Tower, 16th Floor
  Givatayim, Israel
  5320047
  (Address of principal executive offices)
  (Zip Code)
  Therapix Biosciences Ltd. Israeli Share
  Option Plan (2005)
  Therapix Biosciences Ltd. Israeli Share
  Option Plan (2015)
  (Full Title of the Plan)
  C T Corporation System
  111 Eighth Avenue
  13th Floor
  New York, New York 10011
  (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
  Copies of communications to:
  Jeffrey P. Schultz, Esq.
  Mintz, Levin, Cohn, Ferris, Glovsky and
  Popeo P.C.
  Chrysler Center, 666 Third Avenue
  New York, NY 10017
  Tel: 212-935-3000
  Indicate by check mark whether the registrant is a large
  accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See
  the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Accelerated filer
  ☐
  Smaller
  reporting company
  ☐
  Non-accelerated filer
  ☒
  Emerging
  growth company
  ☒
  (Do not check if a smaller reporting company)
  If an emerging growth company, indicate by check mark
  if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act .
  o
  CALCULATION OF REGISTRATION FEE
  Title of securities to be registered
  Amount to be
  registered (2)
  Proposed maximum
  offering price
  per share
  Proposed maximum
  aggregate
  offering price
  Amount of
  registration fee
  Ordinary Shares, par value NIS 0.10 per share (1)
  769,037
  $
  0.14
  $
  107,665.18
  (3)
  $
  13.40
  Ordinary Shares, par value NIS 0.10 per share (1)
  20,880,000
  $
  0.16
  $
  3,340,800
  (4)
  $
  415.93
  Ordinary Shares, par value NIS 0.10 per share (1)
  10,120,000
  $
  0.11
  $
  1,113,200
  (5)
  $
  138.59
  Total
  31,769,037
  $
  4,561,665.18
  $
  567.92
  (1)
  American Depositary Shares (the "
  ADSs
  "),
          evidenced by American Depositary Receipts, issuable upon deposit of the Ordinary Shares registered hereby, par value NIS 0.10 per
          share (the "
  Ordinary Shares
  "), of Therapix Biosciences Ltd. (the "
  Registrant
  " or "
  Company
  "
          ) are registered on a separate registration statement on Form F-6 (File No. 333-197509). Each ADS represents forty (40) Ordinary
          Shares.
  (2)
  This Registration Statement on Form S-8 covers the following Ordinary Shares of Therapix Biosciences Ltd. (the "
  Registrant
  "):
  (i) 769,037 Ordinary Shares issuable upon the exercise of options granted prior to the date hereof under the Registrant's Israeli Share Option Plan (2005) (the "
  2005 Plan
  "), (ii) 20,880,000 Ordinary Shares issuable upon the exercise of options granted prior to the date hereof under the Registrant's Israeli Share Option Plan (2015), as amended (the "
  2015 Plan
  "), (iii) 10,120,000 Ordinary Shares available for issuance pursuant to future grants under the 2015 Plan, and (iv) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "
  Securities Act
  "), an indeterminate number of additional shares that may become issuable under the terms of the 2015 Plan by reason of any share split, share dividend, recapitalization or other similar transaction effected without the Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of the Registrant's Ordinary Shares.
  (3)
  Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of US$0.14 per share, the weighted average exercise price of the 1,090,361 Ordinary Shares issuable upon exercise of outstanding options under the 2005 Plan as of the date of this Registration Statement.
  (4)
  Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of US$0.l6 per share, the weighted average exercise price of the 23,100,000 Ordinary Shares issuable upon exercise of outstanding options under the 2015 Plan as of the date of this Registration Statement.
  (5)
  Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) and (c) on the basis of the average of the high and low prices of the Registrant's ADSs as reported on the Nasdaq Capital Market on June 20, 2018 with respect to Ordinary Shares reserved for issuance pursuant to future grants under the 2015 Plan.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS
  Item 1.   Plan
  Information*
  Item 2.   Registrant
  Information and Employee Plan Annual Information*
  * The documents containing the information specified in this
  Part I of Form S-8 (plan information and registration information and employee plan annual information) will be sent or given to
  employees as specified by the Securities and Exchange Commission (the "
  Commission
  ") pursuant to Rule 428(b)(1)
  of the Securities Act of 1933, as amended (the "
  Securities Act
  "). Such documents are not required to be and
  are not filed with the Commission either as part of this registration statement (this "
  Registration Statement
  ")
  or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference
  in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements
  of Section 10(a) of the Securities Act. The Registrant will provide a written statement to participants advising them of the availability
  without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including
  the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge,
  upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b), and will include the address
  and telephone number to which the request is to be directed.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3.   Incorporation
  of Documents by Reference
  The following documents filed by Therapix
  Biosciences Ltd. (the "
  Company
  ") are incorporated herein by reference:
  ●
  Annual Report on Form 20-F for the year ended December 31, 2017, filed on April 30, 2018 (File No. 001-38041);
  ●
  Our Reports on Form 6-K filed on January 16, 2018, March 20, 2018, April 9, 2018, April 20, 2018, April 27, 2018, May 4, 2018, May 9, 2018, May 17, 2018, June 6, 2018 and June 14, 2018; and
  ●
  the description of our ADSs and ordinary shares contained in our Form 8-A filed on March 21, 2017 (File No. 001-38041).
  In addition to the foregoing, all documents
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended
  (the "
  Exchange Act
  "), prior to the filing of a post-effective amendment indicating that all securities offered
  hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference in
  this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained herein or
  in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be
  modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other
  subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
  this Registration Statement.
  2
  Item 4.   Description
  of Securities.
  Not applicable.
  Item 5.   Interests
  of Named Experts and Counsel
  Not applicable.
  Item 6.   Indemnification
  of Directors and Officers
  Indemnification
  The Israeli Companies Law (5759-1999) (the
  "
  Companies Law
  ") and our articles of association provide that the Registrant may indemnify an office holder
  against:
  ●
  a financial liability imposed on him or her in favor
  of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement
  or arbitrator's award approved by a court; However, if an undertaking to indemnify an office holder with respect to such
  liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the Board of Directors,
  can be foreseen based on the company's activities when the undertaking to indemnify is given, and to an amount or according
  to criteria determined by the Board of Directors as reasonable under the circumstances, and such undertaking must detail the abovementioned
  foreseen events and amount or criteria;
  ●
  reasonable litigation expenses, including attorneys'
  fees, incurred by the office holder: (i) as a result of an investigation or proceeding instituted against him or her by an authority
  authorized to conduct such investigation or proceeding, provided that (a) no indictment (as defined in the Companies Law) was
  filed against such office holder as a result of such investigation or proceeding; and (b) no financial liability as a substitute
  for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or
  proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof
  of criminal intent; and (ii) in connection with a monetary sanction;
  ●
  reasonable litigation expenses, including attorneys'
  fees, expended by the office holder or charged to him or her by a court relating to an act performed in his or her capacity as
  an office holder, in connection with: (1) proceedings that the company institutes, or that another person institutes on the company's
  behalf, against him or her; (2) a criminal charge of which he or she was acquitted; or (3) a criminal charge for which he or she
  was convicted for a criminal offense that does not require proof of criminal thought;
  ●
  expenses incurred by an office holder relating to an administrative
  enforcement proceeding conducted with regard to such office holder, including reasonable litigation expenses and including attorneys'
  fees;
  ●
  payment to the party injured by the violation; and
  ●
  liability or expense otherwise permitted as an indemnification
  by the Companies Law.
  3
  Our articles of association allow us to indemnify
  our office holders up to a certain amount. The Companies Law also permits a company to undertake in advance to indemnify an office
  holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the
  undertaking should be limited:
  ●
  to categories of events that the Board of Directors determines
  are likely to occur in light of the operations of the company at the time that the undertaking to indemnify is made; and
  ●
  in amount or criterion determined by the Board of Directors,
  at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.
  We have entered into indemnification agreements,
  which were amended following the consummation of our U.S. initial public offering and listing on NASDAQ, with each of our directors
  and with certain members of our senior management. Each such indemnification agreement provides the office holder with indemnification
  to the fullest extent permitted under applicable law and up to a certain amount, and including with respect to liabilities resulting
  from our March 2017 initial public offering in the United States, and to the extent that the directors and officers insurance do
  not cover these liabilities.
  Exculpation
  Under the Companies Law, an Israeli company
  may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an office
  holder from his or her liability to the company, in whole or in part, and for damages caused to the company as a result of a breach
  of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
  in its articles of association. A company may not exculpate a director from liability arising out of a prohibited dividend or distribution
  to shareholders. Our articles of association provide that we may exculpate any office holder from liability to us to the fullest
  extent permitted by law.
  We have entered into exculpation agreements
  with each of our current directors and executive officers undertaking to exculpate and release our office holders from any and
  all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law and including
  with respect to liabilities resulting from our March 2017 initial public offering in the United States.
  Limitations
  The Companies Law provides that we may not
  exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred
  as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
  or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act
  would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally
  or recklessly (as opposed to merely negligently); (3) any action taken or omission committed with the intent to derive an illegal
  personal benefit; or (4) any fine or forfeit levied against the office holder.
  We have obtained directors and officers liability
  insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder
  to the fullest extent permitted by the Companies Law.
  Insofar as the indemnification for liabilities
  arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or persons
  controlling the registrant, we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification
  is against public policy as expressed in the Securities Act and is therefore unenforceable.
  Item 7.   Exemption
  from Registration Claimed
  Not applicable.
  Item 8.   Exhibits
  The exhibits listed on the exhibit index
  at the end of this Registration Statement are included in this Registration Statement.
  4
  Item 9.   Undertakings
  The undersigned Registrant, Therapix Biosciences
  Ltd., hereby undertakes:
  (1)
  to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
  (ii)
  to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and
  (iii)
  to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.
  provided
  ,
  however
  , that paragraphs
  (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the
  Exchange Act that are incorporated by reference in the registration statement.
  (2)
  that, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
  (3)
  to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; and
  The Registrant hereby undertakes that, for
  purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Sections
  13(a) or 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.
  Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to
  the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
  controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  5
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
  on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Givatayim, Israel, on June 21, 2018.
  THERAPIX BIOSCIENCES LTD.
  By:
  /s/ Ascher Shmulewitz
  Name: Ascher Shmulewitz, M.D, Ph.D.
  Title: Chief Executive Officer
  POWER OF ATTORNEY
  KNOW ALL MEN BY THESE PRESENTS that each
  person whose signature appears below hereby constitutes and appoints Dr. Ascher Shmulewitz and Oz Adler, and each of them, his
  true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution,
  for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection
  therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority
  to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either
  of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities
  Act of 1933, as amended, this registration statement has been signed by the following persons on June 21, 2018 in the capacities
  indicated:
  Signature and Name
  Title
  Date
  /s/ Ascher Shmulewitz
  Chairman of the Board of Directors and Chief
  June 21, 2018
  Ascher Shmulewitz, M.D, Ph.D.
  Executive Officer (Principal Executive Officer)
  /s/ Oz Adler
  Chief Financial Officer (Principal Financial and
  June 21, 2018
  Oz Adler
  Accounting Officer)
  /s/ Amit Berger
  Director
  June 21, 2018
  Amit Berger
  /s/ Yafit Stark
  Director
  June 21, 2018
  Dr. Yafit Stark
  /s/ Eric So
  Director
  June 21, 2018
  Eric So
  /s/ Zohar Heiblum
  Director
  June 21, 2018
  Zohar Heiblum
  /s/ Stephen M. Simes
  Director
  June 21, 2018
  Stephen M. Simes
  6
  SIGNATURE OF AUTHORIZED REPRESENTATIVE
  IN THE UNITED STATES
  Pursuant to the Securities Act of 1933,
  as amended, the undersigned, C T Corporation System, the duly authorized representative in the United States of Therapix Biosciences
  Ltd., has signed this registration statement on June 21, 2018.
  C T Corporation System
  By:
  /s/ Brian Mueller
  Brian Mueller
  Assistant Secretary
  7
  EXHIBITS
  Exhibit No.
  Description
  4.1
  Form of Amended and Restated Depositary Agreement (filed as Exhibit 1 to the Post-Effective Amendment No. 1 to Form F-6 (File No. 333-197509) filed on December 7, 2016, and incorporated herein by reference).
  5.1*
  Opinion of Horn & Co. - Law Offices, Israeli counsel to the Registrant, as to the validity of the ordinary shares (including consent)
  23.1*
  Consent of Kost Forer Gabbay & Kasierer (A Member of Ernst & Young Global), independent registered public accounting firm
  23.2*
  Consent of Horn & Co. - Law Offices (included in Exhibit 5.1)
  24.1
  Power of Attorney (included in the signature page to this Registration Statement)
  99.1
  Therapix Biosciences Ltd. Israeli Share Option Plan (2005) (filed as Exhibit 10.6 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on November 4, 2016, and incorporated herein by reference).
  99.2
  Therapix Biosciences Ltd. Israeli Share Option Plan (2015) (filed as Exhibit 10.5 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on November 4, 2016, and incorporated herein by reference)
  8